Observational studyMedicine2025
Comprehensive analysis of clinical, pathological, and molecular risk factors affecting the prognosis of patients with glioma.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gliomas are the most common primary intracranial tumors in adults, characterized by marked heterogeneity in clinical course and survival outcomes. This retrospective observational study aimed to comprehensively assess the prognostic value of clinical, pathological, and molecular parameters in glioma patients, as defined by the 2021 World Health Organization (WHO) classification. A total of 110 patients diagnosed with primary glioma between January 2015 and December 2024 were included. Clinical data, tumor characteristics, treatment details, and molecular profiles were retrospectively collected and analyzed. Overall survival (OS) was estimated using the Kaplan-Meier method, and multivariate Cox proportional hazards regression was employed to identify independent prognostic indicators. The analysis revealed that multifocal lesions, tumor diameter ≥ 4 cm, and higher WHO grade (III-IV) were significantly associated with shorter OS. In contrast, patients who underwent chemotherapy, had MGMT promoter methylation, carried IDH1/2 mutations, or received ≥ 50% tumor resection demonstrated better survival outcomes. These findings emphasize the prognostic relevance of integrating molecular markers with traditional clinical and histopathological variables. This approach may enhance the precision of survival predictions and inform personalized therapeutic strategies in glioma management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.